Compare QFIN & ANIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QFIN | ANIP |
|---|---|---|
| Founded | 2016 | 2001 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2018 | 1999 |
| Metric | QFIN | ANIP |
|---|---|---|
| Price | $13.17 | $81.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $22.20 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 957.0K | 242.8K |
| Earning Date | 05-18-2026 | 05-08-2026 |
| Dividend Yield | ★ 12.36% | N/A |
| EPS Growth | N/A | ★ 419.23 |
| EPS | N/A | ★ 1.28 |
| Revenue | N/A | ★ $206,547,000.00 |
| Revenue This Year | N/A | $21.01 |
| Revenue Next Year | N/A | $17.59 |
| P/E Ratio | ★ $2.21 | $25.41 |
| Revenue Growth | N/A | ★ 2.47 |
| 52 Week Low | $12.29 | $56.71 |
| 52 Week High | $46.18 | $99.50 |
| Indicator | QFIN | ANIP |
|---|---|---|
| Relative Strength Index (RSI) | 46.41 | 54.48 |
| Support Level | $12.41 | $77.46 |
| Resistance Level | $14.54 | $83.58 |
| Average True Range (ATR) | 0.45 | 2.87 |
| MACD | 0.03 | 0.28 |
| Stochastic Oscillator | 33.70 | 40.38 |
Qfin Holdings Inc Formerly Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.